Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.

New late-breaking data presented at TCT confirmed that the first FDA-approved TTVR system for TR is associated with a much better quality of life than medical therapy alone after one year.

“This document represents a collective effort to refine and advance the standards of care in STEMI management," according to one cardiologist behind the project. 

A new study found cumulative radiation exposure of 16 mSv to red bone marrow can cause an increased rate of some hematological malignancies.

ShortCut, which gained the FDA’s breakthrough device designation back in January, is used to split valve leaflets and reduce the risk of obstruction.

Patients often have misconceptions about the different PAD treatments that are currently available. Pedro Martinez Clark, MD, outlined those options for a new video interview.

"The underrepresentation of women in interventional cardiology is a significant concern," according to one cardiologist behind the new campaign. 

Which modality should care teams choose for PCI guidance? While there's an argument to be made for choosing IVUS over OCT, some specialists think the two treatment options are close to equal in terms of patient outcomes.